Company

Founded in September 2019, we are a team of experienced AI/machine learning and business specialists applying state of the art generative AI to drug discovery in close collaboration with biopharmaceutical partners to bring new therapeutics to market across disease areas and positively impact lives.

Our Team

We are a team of experienced AI/machine learning and business specialists applying state of the art generative AI to drug discovery in close collaboration with biopharmaceutical partners to bring new therapeutics to market across disease areas and positively impact lives.

Handol Kim

Mehran Khodabandeh

Zac Alperstein

Peter Guzzo

Roslynn Drewitt-Lange

Marshall Drew-Brook

Marawan Ahmed

Jason Rolfe

Artem Cherkasov

Ali Saberali

Ahmad Issa

Board, Observers & Outsiders

John BoylanPhD, SAB Member (Cell Biology/Oncology drug discovery)

Nancy HarrisonAdvisor (Strategy/ Commercial)

Mads DaugaardPhD, SAB Member (Oncology Biology)

Jennifer HamiltonPhD, Advisor (Strategy/Commercial)

Robert N. YoungPhD, SAB Member (Medicinal Chemistry)

Alexander TropshaPhD, SAB Member (Cheminformatics)

Todd FarrellAdvisor (Strategy)

Frank ChangBoard Director

Funding, Partners & Investors

Founded in September 2019, we are a team of experienced AI/machine learning and business specialists applying state of the art generative AI to drug discovery in close collaboration with biopharmaceutical partners to bring new therapeutics to market across disease areas and positively impact lives.

Recent News & Events

Press Release

Variational AI Files Two US Provisional Patents for Potential COVID-19 Drug Created by Generative AI

Variational AI, developer of the Enki™ generative artificial intelligence (AI) drug discovery platform to redefine the economics of drug development, today announced that the company has filed two provisional patents with the United States Patent...
Press Release

Variational AI Adds Jennifer Hamilton as Advisor

Variational AI, developer of generative AI-based drug discovery platform for novel kinase inhibitors, today announced that it has added industry and scientific leader Jennifer Hamilton, Ph.D. as a company advisor.
Press Release

Variational AI Adds Leading Oncology Researchers to Scientific Advisory Board

Variational AI, developer of generative AI-based drug discovery platform for novel kinase inhibitors, today announced that it has added industry and scientific leaders Dr. John F. Boylan and Dr. Mads Daugaard to the company’s Scientific Advisory Board.

Variational AI is hiring!

Please see open job listing below or contact us if you would like to join the team in the area of machine learning, computational medicinal chemistry, and business development.

View Positions

Contact Us